IBCSG Trial 22-00 Serum Substudy
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 136
- Registration Number
- NCT02393833
- Locations
- 🇮🇹
Istituto Europeo di Oncologia (IEO, Milano, Italy
Afatinib in NSCLC With HER2 Mutation
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 13
- Registration Number
- NCT02369484
- Locations
- 🇨ðŸ‡
CHUV, Lausanne, Switzerland
🇨ðŸ‡USZ, Zürich, Switzerland
🇳🇱NKI-AVL, Amsterdam, Netherlands
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 518
- Registration Number
- NCT02308085
- Locations
- 🇺🇸
Mattoon Charleston Primary Care, Mattoon, Illinois, United States
🇺🇸Sanford Bismark Medical Centre, Bismarck, North Dakota, United States
🇨🇦Mount Sinai Hospital, Toronto, Ontario, Canada
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
- Conditions
- Interventions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 595
- Registration Number
- NCT02129699
- Locations
- 🇦🇹
Univ. Klinik für Innere Medizin V, Innsbruck, Austria
🇦🇹KH der Elisabethinen Linz, Linz, Austria
🇦🇹AKH Wien, Wien, Austria
Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 58
- Registration Number
- NCT02129556
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
🇧🇪Jules Bordet Institute, Brussels, Belgium
🇧🇪CHU Sart Tilman, Liège, Belgium
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
- Conditions
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 222
- Registration Number
- NCT02046733
- Locations
- 🇦🇺
Royal Hobart Hospital, Hobart, Australia
🇪🇸Hospital Universitario 12 Octubre, Madrid, Spain
🇦🇺Coffs Harbour Health Campus, Coffs Harbour, Australia
TRial on the Endocrine Activity of Neoadjuvant Degarelix
- Conditions
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 51
- Registration Number
- NCT02005887
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi di Bologna, Bologna, Italy
🇮🇹Istituto Toscana Tumori, Prato, Italy
🇮🇹Ospedale degli Infermi, Rimini, Italy
Schedules of Nab-Paclitaxel in Metastatic Breast Cancer
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 258
- Registration Number
- NCT01746225
- Locations
- 🇧🇪
CHR de la Citadelle, Oncology-Haematology Unit, Liège, Belgium
🇧🇪CHU Sart Tilman, Medical Oncology, Liège, Belgium
🇮🇪Mid-Western Regional Hospital, Limerick, Ireland
Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 81
- Registration Number
- NCT01652469
- Locations
- 🇦🇹
Krankenhaus Hietzing, Wien, Austria
ðŸ‡ðŸ‡ºNational Institute of Oncology, Budapest, Hungary
🇮🇪St James's Hospital, Dublin, Ireland
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 109
- Registration Number
- NCT01562028
- Locations
- 🇫🇷
Centre Francois Baclesse, Caen, France
🇫🇷Hôpital de Marseille, Marseille, France
🇩🇪Thoraxklinik Heidelberg GmbH, Heidelberg, Germany